Skip to main content

Table 1 Frequencies of amino acid substitutions detected in HCV NS5A protein from mono-infected and HIV/HCV co-infected patients

From: Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil

Amino acid residues

HCV (n = 156)

HIV/HCV (n = 101)

1a (n = 41)

1b (n = 84)

3a (n = 31)

1a (n = 77)

1b (n = 9)

3a (n = 15)

M/L28a

V (1; 2.4%)

V (1; 1.2%)

–

–

–

 
 

I (1; 2.4%)

–

–

I (3; 3.9%)

–

 
 

L (1; 2.4%)

–

–

–

–

 
 

–

P (1; 1.2%)

–

–

–

 
 

–

–

–

T (1; 1.3%)

–

 

Q/R/A30a

H (4; 9.8%)

–

–

H (1; 1.3%)

–

 
 

R (1; 2.4%)

–

–

R (1; 1.3%)

–

 
 

–

K (1; 1.2%)

K (5; 16.1%)

–

–

 
 

–

Q (3; 3.6%)

–

–

Q (1; 11.1%)

 
 

–

–

S (1; 3.2%)

–

–

S (1; 6.7%)

 

–

–

–

L (1; 1.3%)

–

 

L31

–

F (1; 1.2%)

–

–

–

 
 

–

V (2; 2.4%)

–

–

–

 

Y93

–

H (2; 2.4%)

H (2; 6.5%)

–

H (1; 11.1%)

 

Total (RAS)

14.6% (6/41)

6.0% (5/84)

22.6% (7/31)

3.9% (3/77)

11.1% (1/9)

0% (0/15)

  1. HCV hepatitis C virus and HIV human immunodeficiency virus
  2. aNS5A: M28 and Q30 are the dominant amino acids in GT-1a; L28 and R30 are the dominant amino acids in GT-1b; M28 and A30 are the dominant amino acids in GT-3a
  3. Bold type represents the clinically relevant resistance-associated substitution (RAS). Data interpreted according to cited references [5, 23, 27, 33, 39,40,41,42]
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us